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OBJECTIVE—b-Cell and islet endothelial cell destruction
occurs during the progression of type 1 diabetes, but, paradoxi-
cally, b-cell proliferation is increased during this period. Altered
glucose tolerance may affect b-cell mass and its association with
endothelial cells. Our objective was to study the effects of glu-
cose and inﬂammation on islet vascularity and on b function,
mass, and insulin in immunologically tolerant anti-CD3 monoclo-
nal antibody (mAb)-treated and prediabetic NOD mice.
RESEARCH DESIGN AND METHODS—The effects of phlor-
idzin or glucose injections on b-cells and endothelial cells were
tested in prediabetic and previously diabetic NOD mice treated
with anti-CD3 mAbs. Glucose tolerance, immunoﬂuorescence
staining, and examination of islet cultures ex vivo were evalu-
ated.
RESULTS—Islet endothelial cell density decreased in NOD mice
and failed to recover after anti-CD3 mAb treatment despite
baseline euglycemia. Glucose treatment of anti-CD3 mAb–treated
mice showed increased islet vascular density and increased in-
sulin content, which was associated with improved glucose tol-
erance. The increase in the vascular area was dependent on islet
inﬂammation. Increased islet endothelial cell density was associ-
ated with increased production of vascular endothelial growth
factor (VEGF) by islets from NOD mice. This response was re-
capitulated ex vivo by the transfer of supernatants from NOD
islets cultured in high-glucose levels.
CONCLUSIONS—Our results demonstrate a novel role for
glucose and inﬂammation in the control of islet vasculature and
insulin content of b-cells in prediabetic and anti-CD3–treated
NOD mice. VEGF production by the islets is affected by glucose
levels and is imparted by soluble factors released by inﬂamed
islets. Diabetes 60:876–883, 2011
S
tudies in NOD mice have described a linear loss of
b-cell mass from the time of initiation of insulitis
and prediabetes through the presentation with
hyperglycemia and afterward, followed by the
complete loss of b-cells (1–3). Treatment of diabetic mice
with anti-CD3 monoclonal antibodies (mAbs) can reverse
hyperglycemia, resulting in the normalization of basal glu-
cose levels. We previously have shown that b-cell regranu-
lation occurs after anti-CD3 mAb treatment (2); however,
the factors that improve insulin content in b-cells are poorly
understood.
The islet vasculature has long been regarded as playing
a crucial role in maintaining b-cell survival and function
(4). This is illustrated by the fact that speciﬁc deletion of
the vascular endothelial growth factor (VEGF) gene in
b-cells reduces the islet vasculature and leads to impaired
glucose tolerance, reduced glucose sensing, and decreased
islet size (5). Similarly, VEGF signaling blockage resulted
in a rapid regression of the islet vasculature (6), whereas
overexpression of VEGF under the rat insulin promoter
improved islet mass after transplantation (7). The ability of
the islet vasculature to respond to blood glucose levels by
modulating blood ﬂow in the islet (8) suggests that the islet
endothelium may respond to changes in metabolic demand
and inﬂammation and affect b-cell function in the setting
of diabetes. Moreover, the role of the islet endothelium in
type 1 diabetes may be more than providing nutrients be-
cause previous reports have shown that islet endothelial
cells express costimulatory markers and may function as
antigen-presenting cells (9,10).
Inﬂammation plays a dual role in the progression and
remission from type 1 diabetes. b-Cell proliferation
increases in NOD.SCID recipients of diabetogenic spleen
cells prior to the development of hyperglycemia (2). Three
previous studies (1,2,11) have shown that b-cell pro-
liferation increases with islet inﬂammation during the
progression of diabetes in NOD mice because by 4 weeks
of age, the proportion of Ki67
+insulin
+ cells in the islets
was signiﬁcantly increased in mice with insulitis compared
with control mice. Anti-inﬂammatory measures, such as
treatment with anti-CD3 mAbs or transfer of Tregs, re-
duced b-cell proliferation 3 weeks after treatment (2).
Similarly, the transfer of diabetogenic spleen cells into
NOD.SCID recipients together with CD4
+CD25
+ regulatory
T-cells not only reduced the rate of diabetes but also de-
creased b-cell proliferation in these mice (2). This para-
doxical fall in b-cell proliferation after anti-CD3 treatment
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ORIGINAL ARTICLEand Treg transfer, despite improvement in glucose levels,
suggests that inﬂammation is required for b-cell replication
or attempts at recovery of b-cell function.
Impaired metabolic control attributed to deteriorating
b-cell mass or function may also affect b-cell function and
replication. Interestingly, the highest levels of proliferating
Ki67
+insulin
+ cells are found just prior to the development
of hyperglycemia and remain high after hyperglycemia (2).
This observation suggests that increased metabolic de-
mand, possibly associated with impaired glucose tolerance
prior to the development of hyperglycemia, may contribute
to the rate of b-cell proliferation. This hypothesis is sup-
ported by the suggestion that increased metabolic demand
in obese patients and changes in insulin sensitivity during
pregnancy may stimulate b-cell proliferation (12). Pechhold
et al. (13) showed that insulin treatment reduced b-cell
proliferation in hyperglycemic NOD mice. Alonso et al. (14)
found that mice treated with glucose infusions over a period
of several weeks showed increased b-cell mass attributed to
b-cell proliferation.
The ways in which inﬂammation and glucose affect
b-cell growth and function in the setting of autoimmunity
has not been directly studied. We therefore studied the
changes in b-cell function, vasculature, and replication
after treatment with anti-CD3 in hyperglycemic NOD mice
to test whether b-cell function or replication can be en-
hanced after immune therapy. We show that glucose and
inﬂammation can promote the recovery of insulin content
in the islets of anti-CD3–treated mice by stimulating VEGF
production in islets.
RESEARCH DESIGN AND METHODS
Female NOD/LtJ and NOD.SCID mice were obtained from the Jackson Lab-
oratory (Bar Harbor, ME) and maintained under pathogen-free conditions.
NOD mice were screened for hyperglycemia at 12 weeks of age and diagnosed
with diabetes when two consecutive glucose levels were .200 mg/dL (2).
Glucose levels were measured in whole blood from the tail vein using
a Glucometer Elite XL (Bayer, Elkhart, IN). Animal use was approved by the
Yale University Animal Use Committee.
Treatment with phloridzin. Prediabetic NOD mice were treated with in-
tradermal phloridzin (PHZ) injections at 0.4 mg/kg per day for 14 days (15).
Blood glucose and the presence of glucosuria were measured 3 h after PHZ
treatment. Glycosuria induced by PHZ was detected for as long as 9 h after the
injection. After 14 days, mice were killed and their pancreata were collected.
Treatment with anti-CD3 mAbs. Diabetic NOD mice were treated with
10 mg/day intraperitoneally (i.p.) of the mAb 145-2C11 (anti-mouse CD3) for
5 days beginning at the onset of hyperglycemia, as previously described (2).
Reversal of diabetes was deﬁned when random glucose levels were ,200 mg/dL
for 2 weeks after diagnosis and persisted for .10 days.
Treatment with glucose. Glucose was injected i.p. at a dose of 4 g/kg per day.
Anti-CD3–treated mice with reversed hyperglycemia for at least 10 days re-
ceived daily injections of glucose or vehicle for 14 days. On day 14, mice were
subjected to an intraperitoneal glucose tolerance test (IPGTT), and sera and
pancreata were collected for additional analysis. In a separate set of experi-
ments, nondiabetic 12- to 14-week-old NOD.SCID mice and 8- to 10-week-old
NOD mice were subjected to 14 days of either glucose or vehicle treatment.
IPGTT. Mice undergoing an IPGTT were fasted overnight. They received
a2 g/kgi.p. dextrose injection. Whole-bloodglucose levels were measuredfrom
the tail vein taken before and 15,30, 60,and, in some experiments, 120minafter
the injection.
Immunoﬂuorescence. Pancreata were resected and ﬁxed for 24 h in 2% PFA.
After ﬁxation, pancreatic tissue was placed in a sucrose gradient and snap
frozen in liquid nitrogen. Noncontiguous 14-mm pancreatic sections were
stained with antibodies to insulin (Invitrogen, Carlsbad, CA), 49,6-diamidine-2-
phenylindole dihydrochloride (DAPI), CD31 (BD Biosciences, San Jose, CA),
and either Ki67 or VEGF (Abcam, Cambridge, MA). The bound antibodies
were detected by immunoﬂuorescent secondary antibodies (Jackson Immu-
noresearch, West Grove, PA). The slides were analyzed by ﬂuorescence mi-
croscopy using an Olympus BX-51 microscope. For whole-tissue sections, 35
images were captured using MosaiX software (Carl Zeiss, Thornwood, NY).
Image analysis and postprocessing were performed using ImageJ (http://rsb.
info.nih.gov/ij/). Numbers of single-color– and dual-color–labeled cells were
counted using functions in ImageJ (colocalization, watershed, and analyze
particles). The total pancreatic section area and insulin
1 cells were measure
using ImageJ (16).
Image capture and automated quantitative analysis. Insulin concentration
was measured on a continuous scale using automated quantitative analysis
(AQUA), as has been previously described (17). In brief, a series of high-
resolution monochromatic images were captured using an automated micro-
scope platform (PM-2000TM; HistoRx, New Haven, CT). Fluorescent chromagens
(DAPI, Cy3-insulin) were used to demarcate insulin
1 cells within each whole-
section image. DAPI staining of cell nuclei was used to generate the nuclear
compartment. Subtracting the generated nuclear compartment from the
masked cell area created a nonnuclear compartment, which included both the
cytoplasm and the membrane. To generate an AQUA score, each pixel was
recorded on a scale of 0 (black) to 255 (white), and pixel intensity was deﬁned
using the following equation: (target pixel intensity) 3 (compartment pixel
intensity/255). Using the target and compartment pixel intensities, the fol-
lowing equation was generated: (sum of all target pixel intensities)/(sum of all
compartment pixel intensities/255) = the AQUA score. All scores are nor-
malized for image-exposure time and bit depth, allowing direct comparison of
different histospot/whole-section scores.
Islet isolation. Islets were isolated from NOD or NOD.SCID mice after di-
gestion with collagenase (Liberase; Roche, Indianapolis, IN) (18). Islets were
handpicked twice with an inverted microscope. To examine the effects of
increasing glucose concentrations on VEGF expression, islets were cultured in
10% fetal calf serum glucose-free RPMI (Mediatech, Manassas, VA) supple-
mented with indicated glucose concentrations for 24 h. In some experiments,
preconditioned islet culture media was collected and added to cultures of
freshly isolated NOD.SCID islets. After incubation, islets were harvested and
total RNA was extracted using an RNAeasy kit according to the manufacturer’s
protocol (Qiagen, Valencia, CA). cDNA was generated using SuperScript II
(Invitrogen).
Studies of glucose effect on endothelial cell number. Puriﬁed islets from
either NOD or NOD.SCID donors were incubated with 5 or 10 mmol/L glucose
for 7 days and then dispersed using trypsin digestion. The cells were stained
for the endothelial cell–speciﬁc marker, BS-1. We used BS-1 rather than CD31
for identiﬁcation of endothelial cells because of CD31 sensitivity to trypsin
digestion. The proportion of BS-1
1 cells was evaluated using ﬂuorescence-
activated cell sorter analysis.
Real-time PCR. Examination of VEGF-120, VEGF-164, and VEGF-188 levels
was quantitated by real-time PCR using SYBR Green (Qiagen, Valencia, CA) on
the iQ-5 multicolor real-time PCR system (Bio-Rad, Hercules, CA). All genes
were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
expression. Data analysis was performed using Biorad IQ-5 analyzing software.
PCR primer pairs were as follows: GAPDH: forward CTGCACCAC-
CAACTGCTTAG, reverse GATGGCATGGACTGTGGTCAT; and VEGF: exon 3
common forward primer ATCTTCAAGCCGTCCTGTGTGC, 120 reverse
TTGGCTTGTCACATTTTTCTGG, 164 reverse CAAGGCTCACAGTGATTTTC-
TGG, and 188 reverse ATCTTCAAGCCGTCCTGTGTGC.
RESULTS
Islet vasculature density is reduced in prediabetic
NOD mice and fails to recover after anti-CD3 treat-
ment. Examination of prediabetic mice showed impaired
glucose tolerance in 13-week-old NOD mice when com-
pared with 9-week-old NOD mice (Fig. 1A; area under the
curve at 9 weeks = 8,702 vs. at 13 weeks = 11,195; P ,
0.05). Previous studies have described a decline in islet
vascular area in NOD mice during the progression of di-
abetes (9), but the relationship between these changes and
the impairment of glucose tolerance in NOD mice has not
been directly evaluated. We therefore studied the islet
vascular area in prediabetic mice and after recovery from
hyperglycemia in diabetic NOD mice that were treated
with anti-CD3 mAbs. Reduced CD31
+ area was evident
as early as 9 weeks of age when compared with non-
autoimmune NOD.SCID animals (Fig. 1B; P , 0.0001).
Although there was not a direct relationship between
changes in glucose tolerance and islet vasculature during
prediabetes, there was a sharp decline in CD31 area in the
islets at the time of diabetes onset (Fig. 1B and C; P ,
0.0001).
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CD3 mAbs and found that the nonfasting glucose levels
returned to nondiabetic levels of ,200 mg/dL for a period
.2 consecutive weeks (154.9 6 8.2 mg/dL). However,
when challenged with an IPGTT, these mice showed glu-
cose intolerance when compared with 9-week-old NOD
mice (Fig. 1A; area under the curve at 9 weeks = 8,702 vs.
anti-CD3–treated = 16,578; P , 0.0001). In addition, the
endothelial cell density was not normalized after anti-CD3
mAb therapy and remained signiﬁcantly reduced when
compared with NOD.SCID or 9-week-old NOD mice (Fig.
1B; P , 0.001). These results show a loss of endothelial
cells in the islet during prediabetes that is concomitant
with deterioration of glucose tolerance, both of which are
not fully corrected following anti-CD3 treatment.
Variations in glucose load affect endothelial cell
density in prediabetic and anti-CD3–treated NOD
mice. To determine the relationship between changes in
glucose and the CD31
+ cell density, we treated prediabetic
NOD mice with normal (8 weeks old) or impaired (12
weeks old) results from the IPGTT with daily injections
of PHZ for a period of 14 days. PHZ increases renal
clearance of glucose and reduces glucose load (15). First,
we tested PHZ effects on glucose load in normoglycemic
BALB/C during the IPGTT. PHZ injection increased clear-
ance of blood glucose, as indicated by a more rapid re-
turn to baseline glucose levels (Supplementary Fig. 1A).
Daily PHZ injections of 12-week-old NOD mice reduced
endothelial cell density when compared with vehicle-
treated mice (Fig. 2B and Supplementary Fig. 2), without
altering the islet degree of insulitis (Supplementary Fig.
1B). Interestingly, PHZ also decreased the rates of b-cell
proliferation (Table 1 and Supplementary Fig. 3), which is
consistent with the previously described effects of glucose
on b-cell proliferation in prediabetic mice (13). In contrast,
PHZ treatment of 8-week-old NOD mice, with normal
IPGTT results, did not reduce endothelial cell density
(Fig. 2A).
We also tested whether an increase in glucose in mice
with impaired glucose tolerance would have the opposite
effect. Recovered anti-CD3–treated NOD mice showing
a minimum of 10 consecutive days of basal euglycemia
received daily injections of glucose (4 mg/kg i.p.) for 14
days. After treatment, pancreata were collected and islet
endothelial cell density was evaluated. Glucose injec-
tions signiﬁcantly increased endothelial cell density to
a density similar in prediabetic NOD mice when com-
pared with vehicle-treated controls (Fig. 2A and C; P ,
0.04 and P , 0.001). In contrast, similar treatment of
NOD.SCID mice with daily glucose injections failed to
increase endothelial cell density in islets (Fig. 2D). These
data suggest that ﬂuctuation in daily glucose may mod-
ulate endothelial cell density under the conditions of islet
inﬂammation.
FIG. 1. Anti-CD3–treated diabetic NOD mice fail to normalize their IPGTTs and endothelial cell area in the islet. A: IPGTTs of prediabetic mice at
the ages of 9, 11, and 13 weeks (n = 5 each group) and after anti-CD3 treatment (n = 12). B: Quantitative histomorphic analysis of CD31
1 in
pancreatic sections (n = 3 and four mice of islets from prediabetic, diabetic, and anti-CD3–treated NOD mice and n = 3 and four mice at each time
point) (mean 6 SE). The CD31
1 area in the islets was compared with the same in nonautoimmune NOD.SCID mice by ANOVA (top line, P < 0.0001)
and by the Dunnett multiple comparison test (*P < 0.05; ***P < 0.001) and with mice with new-onset diabetes (bottom line, ANOVA P < 0.0001 and
**P < 0.01; ***P < 0.001). C: Immunoﬂuoresence staining samples of representative islets from 13-week-old nonautoimmune NOD.SCID mice,
prediabetic NOD mice, and NOD mice with new-onset diabetes. Blue, DAPI; red, insulin; green, CD31. wk, week. (A high-quality digital repre-
sentation of this ﬁgure is available in the online issue.)
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is associated with improved glucose tolerance and
insulin content in anti-CD3–treated NOD mice. Next,
we tested the physiological consequences of increased en-
dothelial cell density in glucose-treated anti-CD3–treated
NOD mice. Interestingly, despite the presence of impaired
glucose tolerance before treatment, glucose-treated anti-
CD3 mice showed improved IPGTT results when com-
pared with vehicle-treated mice (Fig. 3A and B; P , 0.05).
Fasting insulin levels in glucose-treated mice were higher
than in placebo-treated mice (vehicle = 0.61 ng/mL vs.
glucose = 0.90 ng/mL; P , 0.06); however, no increase in
b-cell mass was detected (Fig. 3C). Therefore, to examine
the effect of glucose on insulin content in individual
b-cells, we used the AQUA score to measure the content of
insulin. The AQUA score has been validated for protein
quantization in histological section of malignant tissues in
which good reproducibility and linearity with protein
content of tissues has been validated (18–23). AQUA score
analysis revealed increased levels of insulin staining per
b-cell in glucose-treated mice (Fig. 3D; P , 0.05). Glucose
treatment of anti-CD3–treated mice did not increase b-cell
proliferation, albeit proliferation was at relatively high
levels in both vehicle- and glucose-treated mice (Table 1).
These results suggest that increased islet endothelial cell
density may promote b-cell function by increasing insulin
content rather than b-cell proliferation after treatment
with anti-CD3 antibodies.
To understand the basis for increased endothelial cell
density after glucose treatment, we measured VEGF pro-
duction in the islets of glucose-treated anti-CD3–treated
mice by histomorphic analysis. Preliminary immunoﬂuo-
rescence staining revealed an increase in VEGF levels in
prediabetic NOD islets compared with NOD.SCID islets
FIG. 2. Glucose modulates endothelial cell density in prediabetic and anti-CD3–treated NOD mice. Histomorphic analysis of pancreata (n ‡ 3p e r
group) CD31
+ area in 8-week-old (A) and 12-week-old (B) prediabetic NOD mice after daily injections of PHZ for a period of 14 days (*P < 0.04).
C: Endothelial cell area in diabetic and anti-CD3–treated NOD mice receiving either vehicle or glucose injections for 14 days. D:A si nC but with
immunodeﬁcient NOD.SCID mice. *P < 0.05; **P < 0.001. Glu, glucose; Veh, vehicle.
TABLE 1
Proliferation levels in islets of prediabetic and anti-CD3–treated
mice
Group Percentage Ki67
+Ins
+ b-cells P
Prediabetic 8 weeks 0.44
Vehicle 0.23 6 0.07
PHZ 0.16 6 0.06
Prediabetic 12 weeks 0.0003
Vehicle 0.75 6 0.11
PHZ 0.27 6 0.07
Anti-CD3–treated 0.87
Vehicle 0.42 6 0.13
PHZ 0.46 6 0.18
Data are means 6 SE. Pancreata from various NOD groups were
stained for Ki67 and insulin. The percentage of Ki67
+Ins
+ cells
were analyzed as described in RESEARCH DESIGN AND METHODS.
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glucose injections resulted in increased VEGF expression in
the islets when compared with vehicle-treated mice (Fig.
4A; P , 0.02), suggesting that VEGF production by resi-
dent or inﬁltrating islet cells can promote islets in response
to glucose. To directly examine the effects of glucose on
endothelial cell numbers, we incubated puriﬁed islets from
either NOD or NOD.SCID donors at either 5 mmol/L or
10 mmol/L glucose for 7 days followed by ﬂuorescence-
activated cell sorter analysis of BS-1
+ endothelial cells.
NOD islets incubated at 10 mmol/L glucose showed better
maintenance of endothelial cells when compared with
islets incubated at 5 mmol/L glucose (Fig. 4B). In contrast,
high glucose levels failed to maintain endothelial cell lev-
els in islets derived from NOD/SCID mice when compared
with islets incubated at 5 mmol/L glucose (Fig. 4B). Quan-
titative PCR analysis of puriﬁed endothelial cells from NOD
islets cultured at 10 mmol/L glucose showed a 4.2-fold in-
crease in the expression of the antiapoptotic BCL-XL gene
(cycle difference from GAPDH: NOD = 1.87 6 0.73 vs. NOD.
SCID = 0.44 6 0.07; P = 0.10), whereas Ki67 gene expres-
sion remained unchanged (data not shown).
Because VEGF-A is the main regulator of endothelial
cell maintenance, we tested whether increased glucose
had a differential effect on VEGF production by islets
from NOD and NOD.SCID mice ex vivo. Puriﬁed islets from
8- to 10-week-old mice were incubated with increasing
concentrations of glucose for 24 h followed by mRNA
extraction. RT-PCR analysis of VEGF-120, VEGF-164, and
VEGF-188 mRNA isoforms revealed a ﬁvefold increase in
VEGF-120 and VEGF-164 production in the islets of NOD
mice, whereas VEGF-188 was undetectable (Fig. 4C; data
not shown and [24]). This increase was evident at glucose
concentrations of 5, 10, 20, and 40 mmol/L (Fig. 4C). In
contrast, hyperglycemia did not induce VEGF production in
cultured islets form NOD.SCID mice (Fig. 4C).
These ﬁndings were consistent with the lack of an effect
of glucose on vascular area in NOD.SCID mice treated
with glucose but left open the possibility that during in-
ﬂammation, islets could acquire the ability to produce
VEGF after direct immune injury or in response to soluble
factors produced by the inﬁltrating cells. To test this, we
cultured NOD.SCID islets with supernatants collected after
a 72-h incubation of NOD islets in 10 mmol/L glucose and
measured VEGF production by real-time PCR. There was
a signiﬁcant increase in VEGF-120 and VEGF-164 after
incubation with islets from NOD but not control NOD.
SCID mice (Fig. 4D). This increase was more pronounced
in the VEGF-164 isoform, suggesting that the VEGF-120
isoform may derive from a non-islet resident cell (Fig. 4D).
These data suggest that inﬂammation can promote the
production of VEGF-A in the islet by a yet-unidentiﬁed
soluble factor.
DISCUSSION
The improvement in insulin secretion that is seen after
immune therapy in NOD mice and most likely during the
“honeymoon” of type 1 diabetes reﬂects the functional
recovery of existing b-cells, possibly with growth of new
cells, but the factor(s) that controls these responses is not
well understood (3). In this study, we have conﬁrmed
previous ﬁndings that in addition to b-cells, the islet vas-
culature density is reduced prior to the presentation of
FIG. 3. Daily glucose injections improve glucose tolerance and increase insulin content in anti-CD3–treated NOD mice. A: Representative IPGTTs
of anti-CD3–treated mice with normal basal glucose levels receiving daily injections of either vehicle (left panel) or glucose (right panel)i n -
traperitoneally (◆, pretreatment; ■, posttreatment). B: Summary of changes in IPGTT results of anti-CD3–treated diabetic mice with normal
basal glucose levels after a 14-day challenge of daily injections of either glucose or vehicle. *P < 0.04 (n = 12 per group). Stained pancreatic section
of vehicle- and glucose-treated mice for insulin
+ cells. C: Total b-cell area. D: AQUA scores of insulin levels per b-cell as described in RESEARCH
DESIGN AND METHODS.* P < 0.03. Ins, insulin.
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islet endothelial cells after presentation of diabetes in NOD
mice further promote glucose intolerance. Moreover,
treatment with the anti-inﬂammatory anti-CD3 mAbs,
which reverse frank hyperglycemia, fails to correct the
impaired IPGTT results, which are associated with re-
duced CD31
1 cells. In addition, we have found that glu-
cose is a regulator of islet vascular density both in the
prediabetic period and after treatment of diabetic mice
with anti-CD3 mAbs, where glucose treatment augments
CD31 density within the islets. This increase in islet vas-
culature occurs in conjunction with an increase in VEGF
production, resulting in enhanced insulin content and islet
vasculature, but not b-cell proliferation, in islets that have
recovered or been spared destruction by the immune at-
tack. The increase in endothelial cell density may be a re-
sult of decreased rates of cell death because the levels of
the antiapoptotic gene BCL-XL were increased in inﬂamed
endothelial cells under the condition of hyperglycemia.
Importantly, this effect of glucose is contingent upon the
presence of inﬂammation. Susceptibility to the effects of
glucose is induced by soluble factor(s) secreted by the
inﬂamed islets in response to hyperglycemia. This soluble
factor produced by inﬂamed islets controls VEGF pro-
duction by resident islet cells.
The ongoing immunological assault on insulin-producing
b-cells in the islet during the progression of diabetes not
only leads to the ampliﬁcation of the immune response to
islet antigens but also results in a gradual deterioration of
glucose tolerance in prediabetic NOD mice. This increase
in metabolic demand imposes a new challenge for re-
maining b-cells to compensate for increased glucose lev-
els, as seen in situations of type 2 diabetes and during
pregnancy (12). Our ﬁnding showing the ability of treat-
ment with the glycosuric agent PHZ to reduce islet vas-
culature suggests that glucose levels may control the islet
vasculature in the prediabetic state by increasing it with
hyperglycemia and conversely by contracting it with re-
duced glucose load. The control of islet capillaries by
glucose would be predicted because their unique struc-
ture, which consists of a basement membrane and fenes-
trations and is important for the control of glucose ﬂow to
the endocrine cells (25). Islet endothelial cells are highly
sensitive to changes in glucose levels because increased
glucose levels in GK rats can increase islet capillary blood
pressure (26). In addition, Nyman et al. (8) have recently
shown that islet blood ﬂow is regulated by glucose in
normal mice without insulitis. In their studies (8), blood
ﬂow to the islet was dramatically increased after the hy-
perglycemic clamp.
However, the effects of inﬂammation on imparting sen-
sitivity of the islet vasculature to glucose had not been
previously identiﬁed. In anti-CD3 mAb–treated mice, which
show improved basal glucose levels but exhibit impaired
FIG. 4. High glucose levels stimulate VEGF expression under the conditions of islet inﬂammation. A: Histomorphic analysis of islets from
the pancreatic section of vehicle- or glucose-treated anti-CD3–treated NOD mice (P < 0.02). B: Puriﬁed islets from 8- to 10-week-old NOD or
NOD.SCID mice were incubated in either 5 or 10 mmol/L glucose for 7 days. After incubation, islets were dispersed and endothelial cell frequency
was analyzed using ﬂuorescence-activated cell sorter of BS-1
+ cells as described in RESEARCH DESIGN AND METHODS. Left panel: A representative
histogram depicting a sample of two NOD or NOD.SCID islet cultures stained for BS-1. Right panel: Summary of the percentage of BS-1
+ cells after
culture in 5 or 10 mmol/L glucose. n = 6 per group; *P < 0.013. C: Puriﬁed islets from 8- to 10-week-old NOD (left) or NOD.SCID (right) mice as in B
were incubated with increasing concentrations of glucose. Quantitative RT-PCR was done for VEGF-120 and VEGF-164 isoforms in the islets.
D: Supernatants from NOD or NOD.SCID islets incubated at 10 mmol/L glucose for 72 h were added to freshly puriﬁed NOD.SCID islets. Quan-
titative RT-PCR was done for VEGF-120 and VEGF-164 isoforms in the islets (*P < 0.05). n ‡ 3 per group.
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lowing anti-CD3 treatment. This recovery of endothelial cell
density is enhanced by daily glucose injections, leading to
improved glucose tolerance and increased insulin content
per b-cell. Based on our previous studies (27), it is likely
that the improved islet vasculature increases the insulin
content of recovered degranulated b-cells, which accounts
for the majority of b-cell mass recovery after treatment with
anti-CD3 (2).
Inﬂammation has been suggested as a stimulant of b-cell
replication because b-cell proliferation is increased in
prediabetic NOD mice and is highest at the time of the
greatest b-cell destruction (2,28). In addition, the micro-
vasculture is also dependent on inﬂammation and can in-
crease by a variety of cytokines. These permissive roles of
inﬂammation on b-cell proliferation and islet vasculature
are supported by our ﬁndings showing no increase in b-cell
replication and islet vasculature after glucose treatment of
immunodeﬁcient NOD.SCID mice. Our new ﬁndings sug-
gest that inﬂammation also affects the islet vasculature
and that soluble products from inﬂamed islets render islet
cells themselves responsive to glucose because NOD.SCID
islets cultured with supernatants from NOD islets acquired
responsiveness of VEGF production to glucose. One can-
didate cytokine capable of stimulating VEGF production
and vessel remodeling is tumor necrosis factor (TNF)-a
(29). The addition of TNF or its closely related family
member, lymphotoxin, can lead to increased VEGF pro-
duction and stimulation of angiogenesis (30). The ability of
the islet endothelium to respond to increasing VEGF levels
may relate to increased expression of VEGF receptors on
endothelial cells during inﬂammation. The addition of TNF
to endothelial cells in culture can indeed result in in-
creased VEGFR2 expression, leading to altered endothelial
cell morphology and angiogenesis (31), which, when com-
bined with increased glucose levels, can lead to increased
vasculature. The effects of the inﬂammatory response on
the extracellular matrix (ECM) also must be considered.
Normal endothelial cell b interactions are largely mediated
via integrins, suggesting that inﬂammation may alter these
conditions. Recently, the role of matrix metalloproteinase-9
was documented in mediating the release of VEGF, thus
increasing the effective concentration of VEGF-165 at the
site of inﬂammation (32). The breakdown of the ECM may
further potentiate angiogenesis and endothelial cell sur-
vival under the conditions of inﬂammation (33). Based on
our ﬁnding of different proportions of VEGF isoforms
produced in response to glucose by NOD islets and NOD.
SCID islets cultured with NOD culture supernatants, we
speculate that both the islet and immune cells are the
sources of VEGF in inﬂamed islets stimulated with glu-
cose, and the possibility of ECM disturbance and in-
creased accessibility of VEGF to activated endothelial
cells require additional investigation.
Our ﬁndings with PHZ are consistent with a recent re-
port by Pechhold et al. (13) in which islet transplantation
or insulin treatment reduced b-cell proliferation in NOD
mice. However, we were unable to detect an increase in
b-cell replication when we treated previously diabetic
mice with glucose or even in prediabetic mice that were
treated with glucose (data not shown). These negative
ﬁndings are in contrast to studies from Alonso et al. (14) in
which chronic hyperglycemia induced b-cell replication in
B6 mice. One factor that may account for these discrep-
ancies may be the way in which glucose was administered.
We gave a single daily dose rather than a continuous
infusion. In addition, the rates of b-cell replication were
already high in our prediabetic and postdiabetic mice
treated with glucose, and, thus, it may not have been
possible to increase the rates of replication further.
Our data suggest a novel role for glucose in the main-
tenance of islet vasculature during the progression of and
recovery from diabetes and the effects of inﬂammation on
imparting sensitivity to these effects. The factor(s) that
render the islet vasculature susceptible to glucose may
identify a means of increasing b-cell function and/or mass
in settings where b-cell mass is compromised.
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